297 related articles for article (PubMed ID: 22540298)
1. Advances in treatment of lung cancer with targeted therapy.
Cagle PT; Chirieac LR
Arch Pathol Lab Med; 2012 May; 136(5):504-9. PubMed ID: 22540298
[TBL] [Abstract][Full Text] [Related]
2. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
4. New molecular targeted therapies integrated with radiation therapy in lung cancer.
Provencio M; Sánchez A; Garrido P; Valcárcel F
Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
[TBL] [Abstract][Full Text] [Related]
5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapies in Lung Cancer.
Chirieac LR; Dacic S
Surg Pathol Clin; 2010 Mar; 3(1):71-82. PubMed ID: 20680095
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
8. Functional drug-gene interactions in lung cancer.
Smida M; Nijman SM
Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of non-small-cell lung carcinoma.
Tiwari D; Brodie SA; Brandes JC
Ther Adv Respir Dis; 2012 Feb; 6(1):41-56. PubMed ID: 21730004
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
13. [Molecular therapy targets in lung cancer].
Le Guen Y; Sabatier L; Le Chevalier T; Soria JC
Bull Cancer; 2003 Dec; 90(12):1055-61. PubMed ID: 14715425
[TBL] [Abstract][Full Text] [Related]
14. The role of new targeted therapies in small-cell lung cancer.
Rossi A; Maione P; Colantuoni G; Guerriero C; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):45-53. PubMed ID: 15207253
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies and small-cell lung cancer.
Rossi A; Maione P; Palazzolo G; Sacco PC; Ferrara ML; Falanga M; Gridelli C
Clin Lung Cancer; 2008 Sep; 9(5):271-9. PubMed ID: 18824449
[TBL] [Abstract][Full Text] [Related]
16. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
17. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
18. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
19. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
20. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess JW; Wakelee HA
Clin Adv Hematol Oncol; 2012 Apr; 10(4):226-34. PubMed ID: 22706483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]